Udifitimod_product_DataBase

Bioactivity	Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases[1][2].
In Vivo	Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 21 days) 在自身免疫性脑脊髓炎模型中显示出抗炎活性[1]。Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 50 days) 降低了胶原诱导性关节炎 (CIA) 模型的临床评分和足爪组织学评分[1]。 Animal Model:
Name	Udifitimod
CAS	1883345-06-9
Formula	C25H33NO2
Molar Mass	379.54
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Bihorel S, et al. Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan;10(1):8-21. [2]. Gilmore JL, et al. Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials. J Med Chem. 2019 Mar 14;62(5):2265-2285.

PeptideDB